Clinical trial · Observational
Early Detection of Cardiac Damage With CMR in Women With Breast Cancer
NCT04046315CI-TRIAL-00044030EARLY-CATCHunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
With this study the investigators will assess early cardiac damage by means of Global Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with anthracycline-based chemotherapy, and to investigate whether myocardial damage as measured with T1 / T2 Cardiovascular Magnetic Resonance (CMR) mapping and plasma hs-Troponin T is related to changes in GLS.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cardiotoxicity | — | UNRESOLVED | — |
| Chemotherapy Induced Systolic Dysfunction | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CMR | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Global Longitudinal Strain (GLS) change after chemotherapy compared to baseline
- timeFrame
- Baseline and 2 weeks after the last chemotherapy cycle
- description
- A relative reduction in Global Longitudinal Strain (GLS) assessed with CMR
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female * Age ≥ 18 years * A diagnosis of primary breast cancer * Starting (neo-) adjuvant chemotherapy treatment within 2 months after screening * Cardiotoxicity risk score of intermediate, high or very high risk Exclusion Criteria: * Previous radiotherapy or systemic cancer treatment * Cancer metastasis * Life expectancy of less than 6 months * History of myocardial infarction or heart failure * Known contra-indications for CMR * Refusal or inability to provide informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.